SIGA SIGA TECHNOLOGIES INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1010086 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-69.6%
TTM net income YoY-99.1%
TTM EPS YoY-99.0%
Revenue 3-yr CAGR14.6%
Net income 3-yr CAGR—
Margins
Gross margin54.0%
Operating margin-14.2%
Net margin1.3%
FCF margin-22.1%
EBITDA margin-13.0%
Returns
ROE0.4%
ROA0.3%
ROIC (approx.)-15.0%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets5.4%
Debt / equity0.00x
Current ratio24.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-16.81x
Accruals ratio6.0%
Payout ratio6,325.2%
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $94.57M | $138.72M |
| Cost of revenue | $29.70M | $31.29M |
| Gross profit | $64.87M | $107.43M |
| R&D expense | $19.96M | $12.31M |
| SG&A expense | $21.21M | $25.14M |
| Operating income | $23.70M | $69.98M |
| Pretax income | $30.38M | $76.07M |
| Income tax | $7.10M | $16.86M |
| Net income | $23.28M | $59.21M |
| EBITDA | $24.26M | $70.52M |
| EPS (basic) | 0.33 | 0.83 |
| EPS (diluted) | 0.32 | 0.82 |
| Dividends declared per share | 0.60 | 0.60 |
| Weighted avg. shares (diluted) | 71.87M | 71.91M |
| Balance sheet | ||
| Cash & equivalents | $154.97M | $155.40M |
| Receivables | $3.26M | $21.17M |
| Inventory | $49.05M | $49.56M |
| Current assets | $212.86M | $231.04M |
| PP&E, net | $1.09M | $1.30M |
| Goodwill | $898,334 | $898,334 |
| Total assets | $219.47M | $244.34M |
| Current liabilities | $17.99M | $25.33M |
| Total liabilities | $20.65M | $28.53M |
| Shareholders' equity | $198.82M | $215.80M |
| Shares outstanding | 71.61M | 71.40M |
| Cash flow statement | ||
| Operating cash flow | $43.47M | $48.76M |
| Capital expenditure | $355,009 | $42,450 |
| Free cash flow | $43.12M | $48.72M |
| Investing cash flow | -$355,009 | -$42,450 |
| Financing cash flow | -$43.55M | -$43.46M |
| Depreciation & amortization | $562,607 | $538,421 |
| Stock-based compensation | $3.68M | $3.64M |
| Dividends paid | $43.12M | $42.67M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.